Cited 10 time in
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Hong, Sun In | - |
| dc.contributor.author | Ryu, Byung-Han | - |
| dc.contributor.author | Chong, Yong Pil | - |
| dc.contributor.author | Lee, Seungjun | - |
| dc.contributor.author | Kim, Sunjoo | - |
| dc.contributor.author | Kim, Ho Cheol | - |
| dc.contributor.author | Hong, Kyung-Wook | - |
| dc.contributor.author | Bae, In-Gyu | - |
| dc.contributor.author | Cho, Oh-Hyun | - |
| dc.date.accessioned | 2022-12-26T12:32:23Z | - |
| dc.date.available | 2022-12-26T12:32:23Z | - |
| dc.date.issued | 2020-08 | - |
| dc.identifier.issn | 0924-8579 | - |
| dc.identifier.issn | 1872-7913 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/6347 | - |
| dc.description.abstract | [No abstract available] | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Elsevier BV | - |
| dc.title | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b | - |
| dc.title.alternative | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b | - |
| dc.type | Article | - |
| dc.publisher.location | 네델란드 | - |
| dc.identifier.doi | 10.1016/j.ijantimicag.2020.106052 | - |
| dc.identifier.scopusid | 2-s2.0-85087113569 | - |
| dc.identifier.wosid | 000555538400025 | - |
| dc.identifier.bibliographicCitation | International Journal of Antimicrobial Agents, v.56, no.2 | - |
| dc.citation.title | International Journal of Antimicrobial Agents | - |
| dc.citation.volume | 56 | - |
| dc.citation.number | 2 | - |
| dc.type.docType | Letter | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Infectious Diseases | - |
| dc.relation.journalResearchArea | Microbiology | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
| dc.relation.journalWebOfScienceCategory | Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordAuthor | Coronavirus | - |
| dc.subject.keywordAuthor | COVID-19 | - |
| dc.subject.keywordAuthor | Hydroxychloroquine | - |
| dc.subject.keywordAuthor | Interferon | - |
| dc.subject.keywordAuthor | Lopinavir/ritonavir | - |
| dc.subject.keywordAuthor | SARS-CoV-2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
